Key Takeaways:
Revolution Medicines priced concurrent offerings of common stock and convertible senior notes for gross proceeds of approximately $2.0 billion. The offerings were upsized from the previously announced sizes of $750.0 million for the common stock and $250.0 million for the notes, the company said in a statement.
The late-stage clinical oncology company sold 10,563,381 shares of common stock at $142.00 per share. Concurrently, it priced $500.0 million in 0.50% convertible senior notes that will be due in 2033.
The capital raise significantly strengthens the company's balance sheet but introduces share dilution, which could pressure the stock in the short term. The underwriters have a 30-day option to purchase up to an additional 1,584,506 shares.
The issuance and sale of the common stock are scheduled to settle on April 16, 2026, while the notes are expected to settle on April 17, 2026, subject to customary closing conditions. The completion of each offering is not contingent on the other.
The successful offering provides Revolution Medicines with a substantial cash runway to advance its pipeline of RAS-targeted cancer therapies through late-stage clinical trials. Investors will now focus on upcoming clinical data readouts as the next major catalyst for the company.
This article is for informational purposes only and does not constitute investment advice.
